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Vaginal Contraceptives
A Time for Reappraisal?
Vaginal chemical contraceptives deserve a second look.
Until the advent of oral contraceptives and IUDs in the
1960s, creams, jellies, and suppositories were widely used,
both with and without diaphragms and condoms. Then,
vaginal contraceptive use declined. But in the last few
years more effective foam preparations and more conven
ient packaging have been developed. This product improve
ment. coupled with the need for contraceptives that can be
disseminated through nonmedical channels, suggests that
vaginal contraceptives can still playa useful role in family
planning programs.
Vaginal chemical contraceptives, sometimes called
spermicides or topical contraceptives, are made of rela
tively inert base materials which physically block sperm
plus active spermicidal agents which chemically immobilize
or destroy sperm . One of the oldest forms of contraception,
these preparations remain the only method of birth control
used exclusively by a woman which does not require medi
cal intervention or produce systemic effects. Vaginal con
traceptives, like condoms, can be distributed in many
ways-by smal'l stores, bazaars, door-to-door salesmen,
vending machines, as well as in clinics or registered phar
macies. The cost ranges from about $.02 (US) to $.45 (US)
per application .
The major drawback of vaginal methods is the relatively
high failure rate. Compared with users of pills, IUDs, and
even condoms, the users of vaginal contraceptives have a
high incidence of accidental pregnancy. A US survey in
1970 showed that, among couples practicing contraception
for the purpose of either delaying or preventing pregnancy,
31 percent of foam users experienced an unplanned preg
nancy during the first 12 months of use as compared with
6 percent of the pill users, 8 percent of the IUD users,
17 percent of the condom users, and 33 percent of the
rhythm users (135) (see Page H-39).
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woman-years of use-have been reported in several recent
studies in the US (see Page H-45).
There are other factors which limit wide-spread popularity
and distribution of chemical contraceptives. As with all
coitus-dependent methods, these preparations must be
used almost immediately before intercourse, which inter
rupts lovemaking. They must be inserted high into the
vagina, which some women may be reluctant to do. They
must be reinserted for repeated acts of intercourse . They
may cause mild burning or irritation in some women. In
the tropics, many of these preparations require special
protection against heat and humidity. Other difficulties,
including cost, transportation, and promotion, inhibit
commercial distribution, especially in the rural areas of
developing countries.
If, however, the wide-spread medical skepticism about
nonprescription methods of fertility control could be over
come, these problems might also be solved. Certainly there
are many parts of the world in which long standing folk
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traditions support vaginal contraception, making this ap
proach more acceptable at first than more modern tech
niques.
Useful Adjunct Methods
No one today would advocate a family planning program
emphasizing vaginal contraceptives as the primary method
of fertility regulation. The question is whether these prepa
rations fit into modern family planning programs in asso
ciation with other methods and, if so, how. For example,
vaginal contraceptives are sometimes recommended for
use with the IUD during the first few months after insertion
and with condoms during the most fertile time of the
month. During lactation they can reinforce the contracep
tive effect of breastfeeding . The lack of systemic reaction
makes vaginal contraceptives suitable for women who have
had side effects with oral contraceptives or IUDs.

B.C. Aristotle described the use of oil of cedar and frank
incense in olive oil to block the cervical os. Peppermint
juice mixed with honey was mentioned by Dioscarides in
the 1 st century AD. Soranos, in his 2nd century classic
Gynaecology, lists oil, honey, cedar gum, various fruit
acids, and astringents like alum (76). Since environments
that are either strongly acid or strongly alkaline are hostile
to sperm, these early paste and chemical barriers probably
did have some effect in limiting fertility. Salt in an 8 per
cent solution, for example, is highly spermicidal.
During the middle ages, rock salt and alum were frequently
used as vaginal contraceptives. Indian writers in the 8th
century described rock salt dipped in oil or honey as a con
traceptive. Moslem physiCians in the 12th century recom
mended suppositories or tampons containing rock salt,
alum, or various fruit and herb juices. In Europe, a sponge
moistened with diluted lemon juice and inserted into the
vagina was cited in 1732 as an effective traditional
fnethod (76) .
Coitus interruptus was widely practiced by the rural popu
lation in Europe during the 18th and 19th centuries. As
the rapid population growth which accompanied the In-

For young couples, vaginal methods can provide a simple
introduction to contraception. At the other end of the age
spectrum, women approaching menopause may find many
of these products provide welcome vaginal lubrication as
well as protection against a late pregnancy. At all ages
women who have intercourse infrequently or women who
have forgotten to take oral contraceptives regularly can
find in vaginal contraceptives the occasional protection
that is needed.
Laboratory tests have shown that all vaginal contraceptives
currently in use inhibit, in varying degrees, the growth of
venereal disease organisms. Clinical studies now underway
in the United States will determine whether in practice
women using vaginal preparations can expect similar pro
tection against VD.
Most important from the point of view of current distribu
tion facilities, vaginal contraceptives require no supervision
by health personnel. Convenient packaging and simple
graphic instructions are possible . In short, although vagi
nal chemical preparations will certainly never replace oral
contraceptives, sterilization, IUDs, and condoms, they can
serve as a convenient back-up or alternative techniques.

HISTORY
The insertion of pastes, jellies, and various mixtures into
the vagina in order to prevent conception is surely among
the oldest and simplest methods of fertility control. As
early as the 19th century B.C. the Egyptians were mixing
honey, natron (sodium carbonate), and crocodile dung to
form a vaginal contraceptive paste. In the 4th century
H-38

Fig. 1. Examples of Various Vaginal Contraceptives
Top row (I-r): Antemin Cream (UK), Immolin Cream
Jel (USA), Neo Sampoon Loop Foam Tablets (Japan),
CCC Foam Tablets (Japan)
Middle row (I-r); Emko Foam (USA), Delten Foam
(USA). C-Film (Switzerland)
Bottom row (I-r): Rendells Suppositories (UK). CCC
Jelly (Japan), Gynomin Foaming Tablets (UK)

phragm, invented in 1882 by Dr. W ilhelm M ensinga, and
of cream bases for use either alone or with devices f itted by
physician s. During t he 1920s and 1930s, n umerous vagi
nal suppositories an d foaming tablets, many containing
organo-met all ic compounds such as mercury, quin ine,
chinosol, lactic acid, bori c aci d, or bu rnt alu m, were
marke ted in the United Stat es and Europe. Beca use many
physician s still refused to advise on or recommend birth
co ntro l, vagin al contraceptives w ere sold primarily over the
counter or by mail to consumers who were not prot ected by
any official standa rds of safety or effectiveness.

dustrial Revolution brought people to the cities, additional
forms of contraception became accessible t hrough the
marketplace. The first com merc ial vaginal contraceptive
w as developed in 1885 by Walter Rendell, an English
pharmacist. who prepared a suppos itory of soluble cocoa
butter plu s quinine sulfate (7). (Quinine sulfate was re 
placed by hydroqu inone, a more potent spermicide , in
1939 when it was discovered tha t the sperm icidal effect of
quin ine su lfate was impaired by cocoa butter.)
In the late 19th century, Anni e Besant, t he Engli sh feminist
leader who chall enged laws prohibiting the distribution of
contrace ptive information, was recom mend ing a sponge
soaked in Quin ine solution as a spermicida l vaginal bar
rier. Several Dutc h physicians in the late 1880s recom
mended va gina l pl ugs made fro m soap. In 1895, W. P.
Chu nn in the United States suggested vaginal suppositories
of cocon ut butter with boric acid, tann ic acid, or bichlori de
of merc ury (76). Together w ith coitus interruptus, these
vaginal methods, both homemade and commercial, w ere
wide ly used before t he development of latex rubber per
mitted mass manufacture of che ap reliable condoms.

Today in ma ny part s of t he w orld homemade vagina l
methods and simple spermi cides are still used. A tampon
of cotton waste and m ust ard oil , for exa mple, is popular
in so me regio ns of India, and douch es of Coca-Co la, w h ich
is moderat ely acid and sperm icida l, have rep ortedly served
the same purpose elsewh ere (130,132).

Surface Active Agents
Compared w ith the volume of research required in recent
years to develop steroidal contraceptives and IU Ds, rela 
tively little study has been devoted to sperm icidal prepa ra
tions. The modern trend has been toward vagi nal contra
ceptives which combine a spermicidal agent of proven

Grad ual recogn itio n by the medi cal profession of th e need
f or more reliab le f orms of contraception spurred the devel
opment of sper micidal je llies to be used with the dia
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potency with a base material, or vehicle, as it is usually
called, that will dissolve or disperse rapidly throughout the
vagina and not irritate either the woman or her partner.
At the same time, concern for toxicity and consumer safety
has led some manufacturers to eliminate possibly haz
ardous compounds, such as mercury and hydroquinones,
from vaginal contraceptive products. Other substances
which offer greater surface action and are less likely to be
irritating, absorbed systemically, or harmful to a fetus have
been substituted.
A critical development in the early 1950s was the discovery
that surface active agents (surfactants) such as nonyl
phenoxy polyethoxy ethanol (nonoxynol-9) were effective
spermicides. Unlike many of the earliest commercial formu
lations, these are neither strongly acidic nor irritating to
the vagina. They are increasingly used as the principal
active ingredients in modern preparations (see Table 1).

Application and Packaging
Not only the ingredients themselves, but also the methods
of application and packaging have been changed and im
proved. In the early 1930s chemical suppositories and
foaming tablets were inserted with the fingers. By the late
1940s plastic applicator tubes with plungers were devel
oped so that jellies could be inserted high in the vagina.
When vaginal creams were introduced in the mid-1950s,
the same applicator design was used. In recent years,
single-dose tampon-shaped applicators, pre-filled at the
factory and disposable after use, have been developed.
In the late 1950s Joseph Sunnen, a St. Louis manufacturer
and family planning enthusiast, developed Emko, a vaginal
contraceptive foam containing nonoxynol-9 and ben
zethonium chloride in a pressurized container. It was first
marketed in 1961. Ortho Pharmaceuticals followed with
Delfen contraceptive foam in 1963.
The first foams came in glass bottles. Because foam could
not be discharged directly into the vagina, single-dose
applicators like those for creams and jellies were included.
The applicator had to be filled just before coitus, sincefoam
in the applicator lost its stability and became liquid after
several hours. Most foams are still applied this way.
In 1970 Emko introduced a single-dose applicator which
the user can fill as much as one week in advance. The
preparation is transferred from the can to the applicator as
a liquid which, when applied, becomes foam in the vagina.
Emko marketed a tampon-shaped container-applicator in
1974. Factory-filled with six premeasured doses, it remains
ready for use indefinitely and produces foam upon applica
tion. The cost is high, about $1 .80 (US) for six applications,
but it may be reduced in time.
In Japan, the Eisai Company has developed small foam
tablets with a new surface active agent, p-methanyl
phenyl polyoxyethylene (8.8) ether, commonly called
TS-88. The tablets are round with a hole in the center
and look somewhat like white Life-Saver candies. They
foam quickly and have a strong spermicidal effect.
Water-soluble contraceptive fi 1m is the newest form of
vaginal contraceptive. In Hungary several years ago
H-40

Hotay developed a water-soluble plastic (polyvinyl alcohol)
film as a base for the spermicide cetyl pyridinium bromide
(CPB). He called this C-film (72). With nonoxynol-9 as the
spermicide, C-film is now patented by USV Pharmaceutical
Corporation and licensed for manufacture and sale by a
British, a Swiss, and an Italian drug firm. Studies are being
conducted in a number of European countries, and C-film
is sold in Britain as an adjunct contraceptive method.

MODE OF ACTION
There are four basic types of chemical contraceptives used
vaginally-creams, jellies, and pastes, which are squeezed
from a tube; suppositories; foams, either in tablet form or
pressurized containers; and soluble films (see Table 2).
Each preparation has two components: a relatively inert
carrier base or vehicle and an active spermicidal agent. All
operate both mechanically, by forming a barrier to delay
sperm progression, and biochemically, by immobilizing or
destroying the sperm which have been blocked.
Products squeezed from a tube include creams, jellies,
and pastes. These diHer mainly in physical characteristics.
Jellies a nd pastes are made from a variety of water-soluble
bases, such as gelatin or gum tragacanth. The base material
and spermicide incorporated within it liquify at body
temperatures and disperse rapidly when they come in con
tact with vaginal secretions. About four or five grams of
jelly or paste are squeezed from the tube into a special
applicator used to insert the product into the vagina.
Creams, on the other hand, are made from water-insoluble
fats, such as stearates or glycerin, which are compounded
into an emulsion with the active spermicide dissolved in
the aqueous portion (72). These preparations tend to re
main wherever they are discharged into the vagina and
not to disperse further. Thus correct positioning of the
applicator is important. Creams provide protection within
two to three minutes after application. Like jellies, they are
packaged in tubes and require special applicators.
Suppositories, sometimes called pessaries or vagitories,
are either water-soluble gelatin-based or water-insoluble
wax-based. They are designed to dissolve at body tempera
ture, releasing active agents which, if placed high in the
vaginal canal, will coat the cervix and vagina. For optimal
effectiveness, most suppositories should be inserted about
15 minutes before coitus. Spermicidal action then lasts
about 20 minutes to one hour. Special packaging is re
quired to prevent damage from heat and humidity.
Foam products are available in tablet form or in pres
surized containers. Foam tablets usually consist of tartaric
acid and bicarbonate of soda with a powder base in which
the spermicide is incorporated. In the presence of vaginal
secretions carbon dioxide is released, generating foam.
This takes from three to ten minutes depending on the
product. Some manufacturers recommend moistening the
tablet with a small amount of saliva or water before in
serting it, so that foaming action is hastened. As the foam
carrying the spermicide disperses over a broad surface area
of the vagina, it produces a discernible amount of heat. No
special applicator is needed, but moisture-proof packaging
is required.

Table 1-Active Ingredients in Selected Vaginal Contraceptives, 1973-1974
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Ramses Contraceptive Vaginal Jelly (Schmid
Laboratories, I nc., USA)

•

•

Creams and Pastes:
Antemin (Coates & Cooper Ltd., UK)
Conceptrol (Ortho Pharmaceuticals, USA)
Delfen Cream (Ortho Pharmaceuticals, USA)

•

Immolin (Schmid Laboratories, Inc., USA)

•
•
•
•

Suppositories:
Lorophyn (Eaton Laboratories, Inc., USA)

•

•
•

Syn·A-gen (Dr. Herbrand KG, G FR)
Foaming tablets:
Antibion (Patentex GmbH, GFR)

•

•

Gynomin (Coates & Cooper Ltd., UK)
Neo Sampoon Loop (Eisai Co. Ltd ., Japan)

•

Semori (LuitpoldWerk, GFR)

•

Patentex (Patentex GmbH, GFR)
Soluble film:
C·film (USV International, Belgium)

•

•

Syn-A-gen (Dr. Herbrand KG, GFR)

Emko Foam (The Emko Co., USA)

•

•

Speton (Temmler-Werke, GFR)
Aerosol foams:
Delfen Foam (Ortho Pharmaceuticals, USA)

•

•

Rendells (W.J. Rendell Ltd., UK)

•
•
•

•

•

Isurface active agents may also possess bactericidal properties.
2use with diaphragm recommended by manufacturer .

SOU RCE: Physician's Desk Reference , 1973; American Medical Association Bureau of Drugs; product labels and in serts; and personal
communications with manufacturers.
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Pressurized foam products, com m only called aerosol
foams, consist of an o il and water e m ulsion stored under
gas pressure. The liq uefied gas prop ellant, w hen re leased,
prod uces the foam . Depend ing on the type of contain er, the
foa m is eith er released into an applicator or, in newer de
sig ns, disc harged d irectly into th e vagina, where the foam
disperses w idely and provides immediate protection .
Some foams can be inserted as much as one hour before
coitus.

Soluble films use polyvinyl alcohol and gly cerine, sodium
carboxy methyl cel lulose (CMC), or rice paper to carr y
spe rm icides. C-f il m is a four em sq uare piece of trans
parent, w ater-sol uble, paper-l ike plastic impregnated with
nonoxyno l- 9 . It requires no special applicator but is fo lded
once and inserted into t he vagina by hand. C-fi lm should be
placed in th e vagi na 30 m inutes befor e coitus (98) .

Althou gh Lagap SA. the Sw iss m an ufacturer, suggests in its
packa ge i nsert that C-fil m can al so be placed over t he peni S
before coitus li ke a condom , this techn ique is not con 
sidered highly effective (1 ).

Other fil ms are made of different substances . For example,
one Italia n con tr acept ive film uses r ice pa per as its base;
an India n f ilm uses ure a as th e spermi cide althou gh its
poten cy is doubtful (70, 13 2 ). Befo re us e soluble fi lm con
tra cep tives must be protect ed against hum idity and
moisture.
Biochemical Acti o n
The ingredients w hich determine a particular product's
spermicidal or biochemical action may be predominately
surface active, bactericidal, or hi gh ly acidic. Frequ ently
two or more of these ingredients are co mb ined in a s ingle
product (see Table 1).

Surface active agents are believed to attach themselves
to the spermatozoa , inhibiting oxygen uptake and fructoly
sis (the splitting up of fructose -sugar). Their primary
action is in breaking down the sperm wall (15). The sim
plest explanation, as Hardy and Wood put it, is that "they
reduce the surface tension at the cell surface and thus in
directly kill the spermatozoa by osmotic imbalance" (72).
Among the most commonly used surface active agents are :
nonylphenoxy polyethoxy ethanol (nonoxynol-9), p
diisobutyl phenoxy polyethoxy ethanol, methoxy polyoxy
ethylene glycol 550 laurate, and p-methanylphenyl poly
oxyethylene (8.8) ether (TS-88) (see Table 1).

The bactericidal agents used most frequently as spermi 
cides are phenyl mercuric acetate (PMA), quinine com
pounds , quartenary compounds, and ricinoleic acid and its
compounds. They act by combining with the sulfur and
hydrogen bonds within the spermatozoa, thus disrupting
their metabolism (72). Actually the distinction between sur
face active and bactericidal is not always clear since some
bactericides act by altering the surface characteristics and
potency of bacteria (13,17 ,37). Surfactants and bacteri
cides together often have a synergistic effect, making the
combined product a more effective spermicide than any
one of the ingredients alone . Administered under direct
medical supervision at frequent intervals or in concen
H-42

trated for m , some of t hese agents may also be effective
aga inst comm on vaginal infections such as tr ichomoniasis
or monol iasis, but t her e is no evidence th at th ey have a
significant bact er icidal effect i n norm al contraceptive use.

Highly acidic agents most likely to be used as sperm icides
inc lude lactic acid, boric acid, tartaric and citr ic acids,
and g u m acacia , w hi ch w as a lso used in anci ent Greecefor
blocking t he cervix. So meti mes small quant ities of acidic
agents ar e used in addition to other spermicida l ingredi 
ents.

Quality Control and Safety
Spermic ides pose gen uin e proble m s in drug regu lat ion .
Ma ny prod ucts now in use were introd uced before any
nati on developed soph isticated regu latory authorit ies_ In
Britai n, for exam p le, most products have a license " as of
right " fro m th e Com m ittee for Safety of Medicines, which
w ill revi ew them according to a set timetab le. Altho ugh
some tes ts for spermicidal effectiveness have bee n devel 
oped, few tests have been made to evalu ate safety. Lack of
reported adver se effects du r ing past use is the prim ary
arg ument for t he safet y of existin g form u lations, but any
new prod ucts, such as C-film, wi ll u ndoubtedly be subj ected
to m uch closer scr uti ny.
Biologically, a spermiCide could damage the genetic ma 
te ria l in the sperm head without killing the sperm and lead
to abnormalities after fertilization , or it could be absorbed
in m inute quantities and damage the woman or the devel
oping fetus. The former is unproven and the latter has been
investigated only w ith regard to certain mercury com 
pounds. Although th ere are no studies or data showing that
ph enyl mercuric acetate (PMA) or any other compounds
used in vaginal contraceptives have adversely affected
human users, there are ample data proving the toxic ity and
teratogenicity of other mercury compounds such as methyl
mercury (110,118,156,176). Moreover, there is at least
one Japanese study which showed fetal abnormalities in
albino mice ranging from three to five times higher than in
control groups when a portion of a contraceptive tablet
containing PMA was introduced in the vagina on the
seventh day of pregnancy. In addition to these fetal abnor
malities, which involved primarily the central nervous sys
tem, pathological changes suggestive of acute mercury
poisoning were observed in the livers and kidneys of the
mothers (113). To avoid this danger altogether and also to
avoid the necessity of extensive testing to guarantee
safety, a number of manufacturers have substituted sur
face active agents for the organo -metallic compounds
that were used initially.
In the USA, the Food and Drug Administration (USFDA)
has established an advisory panel, chaired by Dr. Elizabeth
Connell, to review the safety, effectiveness, and labelling
of over-the-counter drugs for human use including over
the-counter contraceptives and other vaginal drug prod
ucts (168). Although the panel has reached nofinal conclu
sions, the following standards have been promulgated by
the USFDA "to determine general recognition that a cate
gory of OTC drugs is safe and effective ... " (1 67).
(i) Safety means a low incidence of adverse reactions or
significant side effects under adequate directions for use and
warnings against unsafe use as well as low potential for

by partially controlled or uncontrolled studies, documented
clinical studies by qualified experts, and reports of sig
nificant human experience du ring marketing . Isolated case
reports, random experience, and reports lacking the details
which perm it scientific evaluation will not be considered .
General recognition of effectiveness shall ordinarily be
based upon published studies which may be corroborated
by unpublished studies and other data.

harm which may result from abuse unde r conditions of wide
spread availability. Proof of safety shal l consist of adequate
tests by methods reaso nably applicable to show the drug is
safe under the prescri bed, r ecommended, or suggested con
ditions of use . This proof shall include results of significant
human experience during marketing . General recognition of
safety shall ordinarily be based upon published studies
which may be corroborated by unpublished studies and
other data.

(iii) The benefit-to-risk ratio of a drug shall be considered
in determining safety and effectiveness .
(ii) Effectiveness means a reasonable expectation that, in
a significant proportion of the target population, the phar 
macological effect of the drug, when used under adequate
directions for use and warnings against unsafe use, will
provide clinically significant relief of the type claimed .
Pro of of effectiveness shall consist of controlled clinical
investigations, unless this requirement is waived on the
basis of a showing that it is not reasonably applicable to the
drug or essential to the validity of the investigation and that
an alternative method of investigation is adequate to sub
sta ntiate effect iveness . Investigations may be corroborated

(iv) An aTC drug may combine two or more safe and effec
tive active ingredients and may be generally recogn ized as
safe and effective when each active i ng redient ma kes a con 
tr ibution t o the claimed effect(s); w he n combining of th e ac
t ive ing redients does not decrease the safety or effectiveness
of any of the individua l active ingredients; an d w hen the
combination , when used under adequate directions for use
and warnings against unsafe use, provides rational concur
rent therapy for a significant proportion of the target pop
ulation.

Table 2-Major Characteristics of Various Types of Vagi nal Chemical Contraceptives
Recomm ended
minimum
interval
bet w een appll ca ·
tio n and co itus 2

Duration of
Spermicidal
Eff ectiven8$S2

Frequentlv Used
Base Materials

Frequently Used
Act ive Ingred ients l

Polyethylene
glycol
Gelatin
Gu m tragacan th

Di·isobutylphen
oxy poly
ethoxy ethanol
POlyoxyethy
lenenonyl phenol
Phenyl mercuric
acetate (PMA)

Tube

Plastic appl icator

2·3 minutes

15 minutes·
1 hour

Stearates
Stearic acid
Glycerin

Nonoxynol-9

Tube or single
dose container

Plastic applicato r

2-3 minutes

10 minutes 
1 hour

Refined cocoa
butter
Stearines
Soap
Glycerin

Nonoxynol-9
Polyethyleneglycol of
monoisoctyl
phenol ether
Polysaccharide
polysuffuric
acid ester

Individual foil
packages

Manual insertion
or with inserter

3-15 minutes

20 m inutes
1 hour

Foaming
tablets

Bicarbona te
of soda
Polyethylene
glycol
Glycerin
Tartaric acid

TS·88
Nonoxynol-9
Chinosol
Polysacch ar ide·
polysulfuric
acid ester
Chloramine
Sodium dichlor
osulphami
dobenzoate

Vial or indio
vidual foil pac k

Manual insertion

3-10 minutes

30 minutes·
1 ho ur

Aerosol
foam

Hydrocarbon
and freon
Polyethylene
glycol
Glycerin

Nonox ynol-9
Benzethonium
chloride

Aluminum or
glass container

Plastic appl icator,
single or mul tiple
dose

None

30 minutes·
1 hour

Manual insertion
after folding

30 minutes

N .A .

Type of
Product

Jelly and
Paste

Mode of
Application

Packaging

I

Cream

Suppesi
tories

Soluble
film

I

Polyvinyl alco·
hoi
Glycerine
Rice paper
Sodium car·
boxymethyl
icellulose (CMC)

,

I

Nonoxynol -9

Plas tic pouch
contain ing
cardboard ma tch·
book-l i ke packet

Isee also Table 1.
21nterval between appl ication and coitus and duration of spermic idal effectiveness vary among products of the same type. Also,
researchers' recommendations for the same product may vary .
N.A. = Not Available.
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(v) Labeling shall be clear and truthful in all respects and
may not be false or mlsleading in any particular. It shall
state the intended uses and results of the product; adequate
directions for proper use; and warnings against unsafe use,
side effects, and adverse reactions in such terms as to render
them likely to be read and understood by the ordinary in
dividual, including individuals of low comprehension, under
customary conditions of purchase and use.
(vi) A drug shall be permitted for OTe sale and use by the
laity unless, because of its toxicity or other potential for
harmful effect or because of the method or collateral
measures necessary to its use, it may safely be sold and used
only under the supervision of a practitioner licensed by law
to administer such drugs.

EFFECTIVENESS
Determining the effectiveness of spermicidal preparations
is a complex and sometimes controversial process. It begins
in the laboratory and continues through animal, clinical,
and even survey data to measure the actual use-effective
ness of vaginal products as compared with other contracep
tives. Even then there is disagreement about the best way
to evaluate coitus-related methods since it is more often
the user than the product which is responsible for failure.

During the first stage of testing, the manufacturer usually
undertakes in vitro tests for spermicidal potency, toxicity,
local reactions, and possible carcinogenic properties. These
are followed by comparable tests in animals, usually rab
bits, since, in its sensitivity to spermicides, the rabbit
vagina has proved more like the human vagina than those
of other laboratory animals (46,152). After the spermi
cide and base are combined, further tests measure the time
required for dissolution, foaming, and product dispersal.
Only then are clinical trials initiated, both with and without
sexual activity.

To measure in vitro the potency of the spermicidal ingredi
ents,various special tests have been devised. Baker in the
1930s developed one of the earliest tests, involving 48 dif
ferent operations (7,8) . Other variations were developed
by Brown and Gamble (20,59,60,61,62), Sander and
Cramer (137), Millman (111), Davidson (36), Carruthers
(24), and Harris (73). Many of these are now incorporated
in the International Planned Parenthood Federation
Agreed Test for Total Spermicidal Power (90,130). The
IPPF test approves preparations if 1.0 ml of a 1 :11 solu
tion immobilizes all sperm in 0.2 ml of semen within 40
seconds after the semen and spermicide are mixed . Each
product must pass the test three times using semen from
three different donors or five times uSing semen from six
different donors (90,130).

There is considerable question, however, whether spermi
cidal potency measured in vitro has any relationship to the
clinical effectiveness of the preparation (2,102). Studies
by Johnson and Masters, for example, suggest that the dis
tribution and mechanical function of vaginal contracep
tives can alter spermicidal potency. After observing simu
lated coitus photographed intravaginally, they concluded
that the manner in which the base material spreads in the
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vagina can determine whether the spermicidal agent, how
ever potent in vitro, will function effectively in vivo . Best
results were achieved with aerosol foams and creams .
Using a point scoring method to evaluate contraceptive
effectiveness at time periods ranging from a few seconds
to eight hours after coitus, they found that only Delfen
Cream (Ortho) and Emko Foam provided full protection
after two injections of semen (87) (see Table 3).
Sobrero's independent studies also confirm that, even
though foam apparently disappears during coitus, the
spermicide is well distributed. It forms a highly potent
coating or film which sperm must traverse if they are to
penetrate the cervical canal (151).
Other formulations were less effective, Johnson and Mas
ters found (86). Jellies did not disperse rapidly or thor
oughly through the vagina, were excessively fluid, and
sometimes caused irritation. Foam tablets varied widely
in their dispersal capability, and some users complained of
vaginal irritations such as burning and itching sensations.
Suppositories often did not melt completely, causing an
insufficient distribution of the contraceptive within the
vagina (86).

Measuring Effectiveness
Even more difficult than measuring the efficacy of the
vehicle and spermicide as separate components is the
attempt to measure the efficacy of the composite product in
actual use. With coitus-dependent contraceptives such as
the condom, diaphragm, and vaginal chemical prepara
tions, consistent use in each and every act of intercourse
is more important than any other factor. Therefore, a dis
tinction is sometimes made between theoretical (or physio
logica I) effectiveness and use-effectiveness. Theoretical
effectiveness measures the intrinsic capability of a specific
contraceptive, when used correctly without human error or
negligence, to prevent conception. Rates of theoretical
effectiveness measure only "method failures" and are
based on Iy upon pregnancies which occurred during regular

Table 3-Comparison of Product Contraceptive
Effectiveness by Point Scoring Method*
Commercial
Contraceptive
Product

1st
Insemination

2nd
Insemination

3rd
Insemination

Total
Points

Delfen Cream

180

180

148

508

Emko Foam

180

180

130

490

Lanesta Gel

170

180

130

480

Lactikol Creme

176

144

100

420

Lactikol Jelly

168

162

61

391

Durafoam Tablets

159

72

3

234

Lorophyn
Suppositories

164

56

2

222

Perfect
performance score

180

180

180

540

'One point is allotted for each vaginal specimen showing all
sperm immobilized; six specimens were taken from each of
30 subjects after each insemination.
SOURCE : Johnson and Masters (87) .

Table 4-Effectiveness of Vaginal Chemical Contraceptives in Selected Major Studies Published Since 1960a
Refar
Author and Date

JELLIES
Margolis, Cavanaugh,
and Erns
1962

ance
N'um
ber

Brand 01
Preparation

Location
01 Study

Characteristics
of Population
Studied

Number

Woman-

01
Women

Months
01 Use

Average
Duration
01 Use
(in Monthsl

Number of

Failure Rates
(Pregnancies per
100 Woman-Y earsl

Pregnancies
Method
Failure

Method
and User
Failure

104

Lan.sta -Gel

USA

Young clinic patients
contacted monthly

259

3,250

12 .5

21

N.A .

7.75

Kasabach
1962

88

Koromex A

USA

Clinic patients

195

2,058

10.6

36

7.58

20.99

Frank
1962

54

Korome)( A

USA

Urban clinic patients;
3 mo. contact

684

6,594

9.6

127

N.A .

23. 1

Koromex.
Lactikol,
Lorophyn,
Ortho-Gynol,

Puena

Young , married, low
income, rUfal;

462

4,987

10.8

150

N.A.

36.09

251

2,915

11 .6

22

3.70

9.06

Clinic patients,
in mid-1950s
Same as above

508

6,783

13.3

35

. 71

6.19

164

2,748

16.8

9

.44

3.93

Combined sta tistics,
6 investigators in 19505

425

4,071

9.5

19

2.06

5.60

56

1,344

2

N .A.

1.79

124

1,058

8 .5

2

0

2.27

587

8,955

15.3

24

0.67

3.22

Tietze. Pai, T aylar,
IndGamble
1961

162

Rico

3 mo. contact

and Precept in
CREAMS
Rovinsky
1964
Tyler
1965

134

Dellen

USA

Medically indigent

clinic patients
164

Dellen
(full dosel
Dellen
(half dosel
Dellen
(hall dosel

USA

64

Syn-A-gen

Belgium

FuruSlwl et al
1968

58

Neo Sampoon
Loop

Japan

Ishihama .,d Inoue
1972

82

Neo Sampoon
Loop

Japan

Dellen

USA

Combined statistics,
1590
11 investigators in 1950s

11,096

7.0

133

4.22

14.38

Durofoam

USA

"Poorly motivated"
clinic patients;
3 mo . contact

240

1,749

7.3

32

N.A.

21.96

162

Fomos

Puerto
Rico

Young, low income,
rural, married

166

1,565

9.4

50

N .A.

38.34

21

Emko

USA

"Intelligent,

130

2,737

21 . 1

4

SUPPOSITORIES
God.ts
1973

N.A .

24

FOAM TABLETS

Tyler
1965

164

Dingle and Tietze
1963
Tietza, Pai, Taylor,
and Gamble
1961

39

AEROSOL FOAMS
Bushnell
1965

Clinic patients,
most aged 25-35

Farmers' wives,
most aged 25-35

0

1.75

motivated"

Carpenter .nd
Martin
1970

23

Emko

USA

"Low motivated
and disadvantaged";
3 mo. contact

1778

17,200

9 .7

45

N.A.

3.14

Bernstejn
1971

14

Emko

USA

Mostly medically

2932

28,322

9.7

94

3.05

3.98

Kleppinger
1965

91

Dellen

USA

Clinic patients;
3 mo. contact

138

1,116

8.1

7

2.15

7.53

Tietze and Lewit
1967

160

Emko

USA

Hospital and
clin ic patients;
' -3 mo. contact

779

5,572

7.1

N .A.

N.A .

28.3

Paniagua. Vaillant.

127

Emko

Puerto
Rico

Low income,
urban, Catholic,
married ;
contact each mo .

142

1,723

12.1

42

N.A .

29.25

128

C·l ilm

Europe

N .A .

716

5,194

7.3

23

N.A .

5.31

Egypt

N.A .

91

1,638

18.0

10

N .A .

7.33

indigent;
3 mo . contact

end Gambia
1961
SOLUBLE FILM

Pariser
1974

b

N.A. = not available.
aAlthough many studies of vaginal chemical contraceptives were conducted before 1960, changes of ingredients in some brands make the
results of some early studies inapplicable to the products as now formulated .
bAfter one year, as calculated by life table method. All other rates are calculated by the Pearl Formula .
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contraceptive practice . Since the rates attributed to method
failure in existing studies range from .4 (164) to 7.6 (88)
per 100 woman-years, t he theoretical effectiveness of
vaginal co ntracept ives would appear to be fairly high (see
Table 4).

Use-effectiveness measures what act ually happens in prac
tice, that is, w hen careless or inconsistent use are con
sidered togethe r with "method failure." It is a more valid
meas ure t ha n theoretica l effectiveness. Use-effectiveness
rates were origin ally calculated by t he Pearl form ula - the
number of pregnancies per 100 woman-years of exposure
and thus may be biased either by the relatively h igh failure
rates of short-time users or by the relative ly low fa il ure
rates of long-time users. A more sophisticated method , li fe
table analysis, wh ich measures discontinuation rates over a
specifi ed length of time (extended use-effectiveness), is
comi ng into wider use .

Cli nica l trials sh ow a great var iation in th e effectiveness
rates of vaginal contraceptives. These trials have taken
place over a 40-year time period, using different types of
vag inal contraceptives, different test populations, and dif
ferent procedures for record keeping and fol low-up (1 1.
41 , 42, 44, 45, 50-53 , 63 , 65 -67, 74, 75, 92 , 129, 139.
155, 159, 163. 171. 174, 178, 179). Furthermore. studies of
use- effectiveness were sometimes biased when irregu lar
users or t hose w ho discon ti nued t he method w ere excluded
from the fina l calculations. Therefore, most of the re sults
are not comparab le w ith one another and certa inl y do not
provide conclusive evidence of th e efficacy of vagi nal
methods or of one brand formulatio n as against another
brand .

Nevert hel ess. some poi nt s do eme rge from recent, larger
studies, w hich are summ arized in Table 4. (Al so see refs_
no. 10,26.55, 103,108,109,1 16,122,124,140.150.) Preg
nancy rates range from about two per 100 woman -years in
several relat ively small clin ica l studies to a high of nearly
40. Th e largest number of consistently low failure rates
(less than five per 100 years of exposu re) are reported in
rece nt research wi th Emko and Delfen fo ams in developed
areas-either among private patients, or those attending
Pla nned Parenthood cli nics who se lected foams volun 
tarily, or in other programs w ith continu ing follow -up. In
several US studies , fo r example. women were introduced to
the product by fami ly planning outreach w orkers of similar
eth nic and social backgro unds who communicated to
potential users their own confidence in the product (14,
21, 23,91 ,1 27, 164 ).

Tw o studies, how ever, contradict the low rates oth er re
sea rch ers have found with foams. Tietze and Lewi t reported
a pregnancy rate of 28.3 after 12 mo nths for 779 US
w ome n using Emko foam. This ra te, calculated by the life
table method, is lower than t he pregnancy rate in the same
study for women who used jellies or crea ms alon e (36 .8)
but hi gher t han that of women w ho used diaphrag ms wit h
je lly (17.9) (160). In a Puerto Rica n study, Pan iagua
et 81 reported a failure rate w ith Emko f oam of almost 30
per 10 0 woman-years (127) (see Tab le 4). These rates are
high in comparison to oral contraceptive or IUD preg
nancy rates.
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Neo Sampoon Loop foam tablets, which are manufactured
in J apan , resulted in pregnancy rates as low as 3.2 in a
recently reported study including 587 Japanese farmers'
wives (82). Other studies utilizing foam tablets, however,
have reported failure rates as high as 38.3 per 100 woman
years (see Table 4).

A multi-center study of C-fi lm, sti ll u npublished. reported
an overall pregnancy rate of 5.3 per 100 woman -years after
5194 woman-months of use (128). On the other hand,
C-f il m fail ed a tes t by the British Family Planning Associa
tion because nine pregnancies occurred among 45 women
du ring 175 cycles, for a pregna ncy rate of 62 per 100
woman years. This is about th e same as the rate which
mig ht be expected among women who use no contracep
tion . Users f ound that the quick-dissolving film tended to
adhere to sticky fingers and was therefore difficult to in
sert (1 ,148).

It has long been known that use-eff ectiveness is related to
experience with t he meth od and to th e stage of fa m ily
fo rmation in w hich the couple find themselves. A recent US
study by Professor Norman Ryder of Princeton based on
survey data has provided f urther insight into the reasons
for contracept ive failur e. Regardless of the specific method
used, contraceptors who w ere t ryi ng to prevent further
pregn anCies entirely were much more successful t han con
traceptors tryi ng mere ly to delay or space pregnancies. Of
th ose using foams to prevent births, 22 percent experi 
enced an unw anted pregnancy compared with 36 percent
of those seeki ng me rely to delay birth s. But in t he entire
study 31 percent of those w ho used foams experienced un 
intended pregnancies, compared with 6 percent of t hose
using pi lls, 8 percent using IUDs, 17 percent using con 
doms, 23 percent using diaphragms, 33 perce nt using
rhythm , and 45 percent using a douche (135) (see Fig. 1).

Over the last decade, va gina l contrace pt ives have
been cri ticized or more often si mply ignored by those
in the fa mily planni ng fi eld because of t he hig h fa ilure
rates. On the one hand, many experts believe t hat theo
retical and use -effect iveness shoul d not be differentiated,
that is, all fai lures should be considered method failures
sin ce intermitten t use of a contraceptive met hod actually
refl ects dissatisf action with it (70,9 9,157 ).

On the other han d, some experts argue that those who
ch oose vaginal methods toda y instead of more effective
co ntracepti ves may have ambivalent vi ews about pre
venting pregn ancy. Therefore they may unconsciously
ch oose and use a method carelessly, wi th resulting high
pregna ncy rates. Although contraceptive effectiveness is
very important in some circumstances, in other cases, for
exa mple w here abortion is readily available, different fac 
tors may w eig h m ore heavily in a couple's choice. Even if
rel atively ineffective, a method which is easy to secure
and use may double or triple the i nterval between births
and thus meet individual or comm unity needs more
readily than a highly effective, sophisticated met hod
which requires the supervision of trained medical per
sonnel (13 6) .

Moreover, for t he infrequent user or for women w ho need
temporary protection after IUD removal or omission of
several pills or for women who prefer not to use orals or
IUDs, vaginal contracept ives, especially foam, provide a
reasonable a ltern ative comparable to condoms. Altho ugh
not as effective as condoms, they do not require th~same
degree of mal e cooperation as do condoms, nor do they
dimin ish penile se nsi tivity as condoms are sometimes
alleged to do.
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USE AND DISTRIBUTION
The Internationa l Pl anned Parenthood Directory of Con 
traceptive s (71) lists co ntraceptives marketed th roughout
t he world, in cl udi ng brand nam es, ma nufacturers, and dis
t ributors of vaginal contraceptives . These inclu de 65
products in tubes (creams, je llies, or pastes), 35 su pposi
tories, 33 foam tab lets, and s ix pressu rized foa ms. Al
t hough aerosol foams are probably the most effective of
t hese, no more th an five f irm s manufacture them beca use
of the large investment in equipment th at is necessary. In
t he USA and Brit ain the num ber of vagi nal products on
the market has decl ined steadily since t he 1950s, wi th only
about one t hird as many produ cts listed in 1971 as two
decades before (7 2).

fou nd that use of foa m had increased from 3.3 perc ent in
1965 to 6.1 percent in 1970. By comparison , in 1973
about 10 mi llion women in the US used oral contraceptives
(131 ) and th ree to fo ur million, IUDs (97 ,166).

One po int is cl ear . The use of vaginal contracept ives has
declined substantial ly since oral contraceptives and IUDs
were intr odu ced in the early 1960s. In 1969 in Japan,
where aborti ons were readily availabl e and orals and IUDs
w ere not legal, about 9 percent of ma rried wom en of repro
ducti ve age used jelli es or foa m tablets (1 23). Elsewhere,
use of vaginal contraception in recent years probably has
not exceeded 5 or 10 percent of th e populat ion of repro 
ductive age . In Melbourne, Australi a, a retrospective
survey of once-married wome n under 60 living w ith their
husbands showed that the use of sperm icides as t he main
method of fa m ily plan ning decli ned f rom 20 percent in the
1930s and 1940s to 2 to 3 percent in th e late 1960s.
From 1965 on, over 30 pe rcent of these Melbournewom en
were using orals (2 2). In Europe , a 1971 survey of family
planning attitudes and practices ind icated that only 1 per
cent of t he married w omen in Great Britain w ere then using
vagi nal ch em ical methods and even few er in Italy, Bel 
giu m, France, and W est Germany (81). A bout 5 percent
in Britain were using spermicides together with dia
phragms or condoms (18).

Promotion and Sa les
Assessing the act ual use and distribution ofthe se products
is difficult (68). Si nce prescriptio ns are not required,
women who sel ect th ese methods are not likely to seek
the advice of physicians, and, in t urn, phYSicians and
famil y pla nn ing programs do not generally recommend or
dispense vaginal co nt racepti ves un less orals, IUDs, or
steri lization are co ntraindicated. On t he w hole, use of
vagi nal methods is f ar less tha n th at of orals, IUDs,
sterilization, or condoms, wh ich have repla ced vaginal
methods in most developed cou ntries. Use of ae rosol foams
and foam table ts, however, is increasing as compared to
jellies and cre ams, and it may increase f urther in many
co untries if t hese products are more r ead ily available and
more vigorously pro moted.
An Internationa l Pl an ned Parenthood Federation survey
estimated that 1,0 41 ,500 ,000 doses of spermicides were
distributed in 1971 in t he 73 cou ntries w here IPPF affi li
ate s w ere able to provi de informat ion (7 8). Two-th irds of
these were in Western Europe . If 100 doses provide one
year's protection for the average couple (177), the IPPF
figure could mean that about 10.4 milli on w omen in those
73 countries we re regular users of va ginal contraceptives.
However, the use of vaginal cont racept ives is often
irregular, and probably many more women use them ,
though not regul arl y.
Estimates vary about the use of vaginal contraceptives in
the USA and other developed coun tries. Accordi ng to one
drug manufacturer's estimate about four million US w omen
now use them (112). Another manufacturer has estimated
there are more tha n two million current US use rs of foam
(142) . The 1970 US National Ferti lity St udy placed the
number of US users of contrace ptive foa m at about 1.5
million in that year (135) . The study, based on a survey
of over 5000 couples in which the wife was under 45,

Before the 1960s, the major US manufactur ers con cen 
tr ated their sales effort on persuading ph YSicians to recom
me nd specific vagi na I contraceptives for use together
with diaphragms fi tted by phYSicians . Thus the most effec
tive vagina l preparati on s were not promoted directly to
the consumer market, but indirectly through the medical
profeSSion.

More recently, as t he di ap hragm has been replaced by
other methods and as pu bl ic discussion of family pla nning
has made direct advertising and pharmacy display of non
prescription contraceptives more acceptable, some manu
facturers have undertaken more vigorou s promot ion and
distribution of va gina l contraceptives . In the USA, for
exa mple, the Emko Company, which produces no co ntra 
ceptives except foam, has taken the lead in public adver
tising , and now supplies 40 percent of the domestic foam
market. The Ortho Pharmaceutical Corporation, on the

The International Planned Parenthood Federation
will provide upon request a full description of the
Agreed Test of Spermicidal Power and a list of
products which have passed the test . The IPPF
Directory of Contraceptives (1971) is also avail
able. Contact:
The Medical Department
International Planned Parenthood Federation
18-20 Lower Regent Street
London SW1 Y 4PW
United Kingdom
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other hand, which manufactures and distributes all types
of vaginal and oral contraceptives as well as many other
medical supplies, promotes its products primarily to phy
sicians. During 1973, Ortho produced about 55 percent of
the foam products sold in US pharmacies as well as about
80 percent of the jellies and creams (80).
In recent years vaginal contraceptives, particularly aerosol
foam and cream products, have been advertised in women's
magazines and in some general interest magazines. In order
not to offend public sensitivities, however, most advertise
ments describe the product in such vague terms that the
message may not be conveyed clearly to the consumer.
Moreover, some douches and other vaginal products are
similarly advertised in such ambiguous terms that con
sumers may think these products also have contraceptive
value, even though they do not. In the USA many state
laws prohibit contraceptive advertisements. US television
accepts advertisements for vaginal sprays and vaginal
douches which are used for cosmetic purposes but does not
accept advertisements for vaginal contraceptives.
There are fewer restrictions on contraceptive advertising
in Europe and Japan, where advertisements appear in both
newspapers and magazines, but not on television. In
Sweden, foam is advertised widely, even at cinema per
formances.
Most developing countries accept family planning adver
tisements which do not mention specific types of contra

ceptives. India, Korea, Sri Lanka, Jamaica, and Kenya
have permitted advertisements for condoms, but so far
vaginal preparations have not been promoted in the same
way.
Sales of vaginal contraceptives are generally permitted
through any retail outlet, although some US states and a
few countries attempt to limit distribution to registered
pharmacies. In certain European countries, such as Ger
many, Sweden, Denmark, and the United Kingdom, vaginal
contraceptives can be purchased in specialty shops which
sell products associated with sex. Mail order sales are
important in Germany and in some other countries.
Sales in Developing Countries
Several studies of contraceptive distribution through
the commercial sector have been made in developing coun
tries. In nine country surveys the Westi nghouse Popu lation
Center interviewed fertile urban couples who had cash
incomes. In Turkey, Pakistan, and Panama, users of foams /
creams or other products amounted to 4 percent of those
interviewed. For Jamaica, the figure was 2 percent. Except
in Pakistan, these users were all supplied through com
mercial channels. In Iran, Korea, the Philippines, Thailand,
and Venezuela, vaginal products were rarely used (172,
173).
A somewhat similar survey by Arthur D. Little Inc . (5)
noted that vaginal contraceptives constituted "a minor
volume of all contraceptives sold through commercial

Table 5-Retail Prices of Selected Vaginal Contraceptive Products in Selected Countries, 1974

Product Name

Approximate Retail
Price in uS$
(as of June 1974)

Number of

Country of Sale

Applications

Annual Sales or Number of Users

Emko Foam

$4.00
$2.89 - $3.25

30
30

UK, F inland, South Africa
USA, Canada

1 million users, USA & Canada
20,000 users, UK
40,000 users, Finland

Gynomin foam tablets

$ .75
$1.10

12
12

UK
South Africa

$50,000 (US), UK
42,200 tubes, South Africa

Duragel

$ .37 + taxes

56

UK

$14,100 (US), UK

Conceptrol cream

$2.63

10

UK

Conceptrol cream premeasured

$2.51

6

Neo Sampoon Loop tablets

$2.11
1.72
1.10
1.48
1.20
1.95
1.80
2.40
1.90

20
20
20
20
20
20
20
20
20

Philippines
Thailand
Hong Kong
Singapore
South Vietnam
Guatemala
EI Salvador
Dominican Republic
Panama

1,000,000 tubes, Japan
530,000 tubes, Asia
55,000 tubes, Africa and
Middle East

Peoples Republic Tablets

$ .05

12

Peoples Republic of China

N.A.

Syn-A-gen/A-gen 53
suppositories

$1.85 - $2.72

Europe (5 countries)
Africa (5 countries)
Asia (11 cou ntries)
Central America
(10 countries)
South America
(2 cou ntries)

5 million suppositories

6

USA

SOURCE: Data from manufacturers. Data on Peoples Republic Tablets from Ohneda (120).
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90,000 tubes, Latin America

channels" in Colombia, Iran, and the Philippines. "The
reasons for the sma II vol ume," accordi ng to the study, were
" lack of consumer demand, restriction on distribution to
the drug network, and lack of product availability. The
authors do not believe that drug firms are likely to in
crease their efforts to promote these products because
of lack of potential consumer demand for them" (5).
Promotion, however, appears to increase consumer
demand. In 1972 a four-month pilot project that provided
pamphlets for pharmacists in Colombia to distribute with
information on orals, condoms, and suppositories produced
a 63 percent increase in suppository sales, an 81 percent
increase in condom sales, and a 26 percent increase in
orals sales. Even in drugstores which did not distribute the
pamphlets, suppository sales increased by 39 percent (6).
An analysis of contraceptive distribution in Nigeria, Ghana,
Kenya, and Uganda during 1970 showed sales of 288,000
vaginal foam tablets in Nigeria and 204,000 in Ghana, with
smaller amounts sold in Uganda and Kenya . There were
some tube cream sales in all four countries (16) . Since sup
positories have been used traditionally by the Yorubas in
Nigeria as abortifacients and since in the minds of some
men vaginal methods are less likely than pills or IUDs to
encourage women to be unfaithful (125), a still larger
market may exist in Africa for these products.
Black noted that, "In West Africa, in particular, 'chemical
sellers: or patent medicine dealers, felt this market was
being held back by inadequate importation of products
rather than by lack of demand." Manufacturers are "un
willing to make any significant promotional investments in
view of the threat to the markets from the increasing flood
of subsidized contraceptives, as supplied through bilateral
aid and distributed by family planning organ izations" (16).
Such evidence, although far from conclusive, suggests that
a market may exist for vaginal products, but that these
products so far have not been vigorously promoted. Nor
have the most effective formulations been the most widely
marketed.

Table 6-Deliveries of Vaginal Chemical
Contraceptives Financed by US Agency for
International Development, by Fiscal Year and
Continent, 1971-1974 1

I

Latin America 2
Foam
Jelly
Asia
Foam
Jelly
Africa
Foam
Jelly
TOTAL
Foam
Jelly

1971

1972

1973

1974

58,945
27,580

64,684
72,232

49,983
90,120

47,931
41,912

10,153
10,092

4,394
34,368

4,664
35,976

406,975
42,120

119,260
14,580

127,794
14,076

100,470
11,988

40,258
8,496

188,358
52,252

196,872
120,676

155,117
138,084

495,164
92,528

lAlso, 4000 containers of vaginal tablets delivered to Africa in
1974. Foams in number of 90 gram units or equivalent; jellies
in number of tubes.
21 ncludes Caribbean .
SOURCE : US Agency for I nternational Development, Com
modity Reports System, December 1974.

Table 7-New Acceptors of Vaginal Products in 11
Government and/or Family Planning Association
Programs, 1971

Country

Bangladesh
Barbados
Pakistan
Ghana
Sierra Leone
Jamaica
Puerto Rico
USA
St. Lucia
Ecuador
German Federal
RepUblic

Total New
Acceptors

New
Acceptors
of Vaginal
Preparations

Acceptors of
Vaginal
Preparations
as Percent of
Total
Acceptors

127,051
3,265
329,245
27,217
701
26,632
44,660
1,263,837
2,390
13,722

54,389
1,081
73,306
4,635
99
2,479
4,033
93,375
146
670

43
33
22
17
14
9
9
7
6
5

2,100

97

5

SOU RCE : Huber (78).

Costs
Retail prices vary considerably according to the type of
vaginal product and the type of distribution outlet. In
general, aerosol foams and premeasured doses of cream are
the most expensive, tubes of cream are in the middle range,
and jellies and foam tablets are the least expensive. Retail
costs per application range from about $.02 (US) to $.45
(US) (see Table 5 for selected prices) . AJapanese manufac
turer has reported that foam tablets are sold in the Peoples
Republic of China for the equivalent of about one-half cent
per tablet (120) .

Bulk costs paid by international donor agencies are, of
course, lower than retail prices, but in all instances the
costs of vaginal contraceptives, like those of condoms, are
increasing . In fiscal 1973 the US Agency for International
Development (USAID) paid $.95 (US) for a 90 gram aerosol
container of Emko with applicator. In 1974 the price was
$1 .10 (US). Since 1.2 grams are required for protection,
the per application cost is approximately one and one-half
US cents. The cost to USAID for 50 grams of Delfen foam
with applicator is $1 .30 (US) . With slightly less than one
gram needed for protection, the per application cost is
approximately two US cents. UNICEF has recently pur
chased Neo Sampoon Loop foam tablets at about $.65 (US)
for 20 tablets, or about three US cents for each applica
tion (121) . These prices should be compared with the cur
rent cost to USAID of approximately three US cents for a
single condom (114) and approximately $.13 for a month's
supply of oral contraceptives (38) when purchased in
quantity.

USAID Shipments
At present the distribution of vaginal contraceptives
through family planning programs is not substantial.
USAID, which is the principal source of subsidized contra
ceptive supplies, has not stressed vaginal contraceptives in
its bulk purchasing because of a deliberate program deci
sion to give first priority to the most effective methods.
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For example, between fiscal years 197 1 and 1974,
USA ID supplied about one mill ion 90·gra m units or t he
eq uivalent of aerosol foams, approximately half of that
in 1974 (see Table 6). USAID suppl ied about 400,000
tubes of jelly over th e same four -year period .
Until 1974, the largest shipments of foam were consigned
to Africa, w he re shortages of med ical personnel may have
delayed t he spread of IUDs and ora l contraceptives, bu t in
1974 shipments to A sia increased a hundredf old . Abo ut
300,000 units were sent t o Ba ngl adesh f or its new family
plann ing program . Pakistan, which stepped up its pro
gram, rece ived about 100,000 units.

Program Distribution
The Internati ona l Planned Parenthood Federation (lPPF)
has gathered data on the choi ce of vaginal aerosol fo am,
foam tablets, je ll ies, and creams by patients In c li nics and
other fami ly plann ing program facilit ies (78). A n extensive
study based on detailed questi onna ires fro m 98 countries
re vealed that in 1971 there were either no new acceptors or
an unknown number of acceptors of vaginal methods re 
ported in 65 country progra ms. These figures, of course,
may be attr ibutable to program decis ions and to the non 
availa bility of va gi nal preparat ions as well as to individual
cons umer choice. Of the 33 countries where government
and lor pri vate fa mi ly planning progra ms d id re cord new
acceptors of va gina l preparati ons, on ly 11 showed 5 per
ce nt or more accepting these methods (see Table 7).
IPPF-supported clinics have not experienced any great in
crease in the use of jell ies, creams or aerosol foam s since
1971. even t hough the use of ot her methods has grow n
substant ially. Foam tablets, on the ot her hand, have be
come more popular. In response to requ ests from local

family planning aSSoCiations, IPPF supplied 16 ti mes as
many foam tablets in 1974 as in 1971 (see Table 8 ). This
increase is caused in part by requests from new programs
in the Phil ippines and in Indonesia , but it may also be the
res ult of vigorous promotion by the Ei sai Company of
Japan of the new Neo Sa mpoon Loop foam tablets. To
supply th ese requests, the IPPF purch ases contra ceptives
directly from the manufacturers as w ell as obt ai ning them
from USAID .

Si nce most fa mily planning adm inistrators have not empha
sized the use of vag inal contraceptives, t he present level
of dema nd for these prod ucts, although not high, probably
reflects the conti nuing preference of some individuals and
a few fami ly planning clin ics. Th e growing interest in non 
cl inical distr ibution by midwives, retai l outlets, bazaars,
pedd lers, and the like- although so fa r focused pr imarily
on condoms and pills- may eventu ally contribu te to wider
use of self-ad ministered vag ina l contraceptive methods.

VENEREAL DISEASE PROPHYLAXIS
If cu rrent rese arch is successfu I, vaginal contraceptives
may be shown to offer an additiona l benefit as a VD pro
phylactic. Stu di es now being carried out by Drs. Cut ler,
Singh, and associates at the Universi ty of Pittsburgh are
directed toward the identif ication of vag inal preparations
with bot h contracepti ve and prophylactic prope rti es (13,
17,30,3 1,32,33,34,95, 143, 144,145,146).

Initial in vitro tests have compared 20 products which are
now in use on the basi s of their effect on Ne isseria gonor
rhoeae and Trepo ne ma pa ll id um (syph ilis). They were

Table a-Vaginal Chemical Contracept ives Provided by t he International Planned Parenthood Federation,
by Calendar Year and Area, 1971· 1974, and Scheduled Deliveries, 1975 (by number of containers)
Product and Area
JELLI ES/CR EAMS
Africa
Asia
leIti n America
and Caribbean
TOTA L
FOAM TABLETS
Africa
Asia
leIti n America
and Caribbean
TO TAL
AEROSOL FOAMS
Africa
Asia
Latin America
and Caribbean
TO TAL

Used
1973

Est imated
Usage
1974

Used
1971

Used
197 2

11 ,900
21 ,083
13,432

11,981
26,936
20,048

13,913
30,242
26,856

16,204
42,396
32,020

46,415

58,965

71,011

90,620

4,208
3,93 1
12,913

17,265
19,341
1,689 b

20,751
114,606
2,540

23,856
286,820
28,940

21,052

38,295

137,897

339,616

17,336
17,661
43,667

15,014
c
12,311
34,017

11,490
54 ,639
35,017

78,664

61,342

101,146

a

a

13,9 46"
51 ,600
36,000
101,546

To Be
Deli ve red
1975

To tal

7,530
16,150
41,984

61,528
136,807
134,340

65,664

332,675

58,000
53,300
102,400

124,080
477,998
148,482

213,700

750,560

7,384
18,850
59,246

65,170
155,061
207,947

85,480

428,178

aexclud ing Tunisia
bexcl uding Trinidad and Tobago
cexcl uding Philippines and Sabah
SOURCE : Internat io nal Planned Parenthood Federation, Report to Donors, September 1972,1973, and 1974 (82,83,84).
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Table 9- Lowest Concentration of 20 Contraceptives Requ ired to Inhibit the Growth
of N. Gonorrhoeae by Two Methods3
Time-Exposure Method
Conce ntration
Contraceptive

IParcent)b

Cartane Vagina l Jelly
Contra Creme
Co ntra Foam
Cooper Crem e
Delfen Cream
Delfan Foa m
Em ko Concentrate
Em ko Concent rate +A
Emko Co ncentrate +8
Emko Co ncent rate + Spermic ide
Emko Fo am
Im molin Vag inal
Koromex A Vaginal J elly
Lanesta Gel
Lorophyn Suppo sitories
Miiex Crescent
Ortho Creme
Orthogynol Jelly
Preceptin Gel
Ramslls Vaginal

10
50
10
1
20
50
50
50
50
20
10
50
10
10
10
10
1
10
1
50

Plate-Dilution Method

Growth after
Exposure IMin .)

pH

4.6
6.9
7.5
6.7
5.2
4.9
7.4
7.1
7.2
7.0
7.3
4.9
6.0
5.6
5.7
5.7
6.2
5.5
5.6
6.7

1

5

10

+
+

-

-

-

-

+
-

+
-

+
-

-

-

-

+
-

+

-

±

-

+
+
+
-

+
+
+

±

-

-

-

-

-

-

-

+

-

-

Concentration
IPe rcen t)

pH

10
10
10
10
10
20
20
20
20
20
10
10
50
10
10
10
1
10

c

Growth

-

7.5
7.5
7.5
7.6
7.6
7.6
7.5
7.2
7.2
7.3
7.4
7.5
7.5
7.5
7.5
7.5
7.4
7.4
7.4
7.5

1

50

d

-

-

-

-

-

-

6

aBacterial suspension for these experiments contained about 10 CFU per 0.1 ml, the inoculated Thayer-Martin selective medium plates
were incubated at 37°C. in CO 2 incubator.
bOnl y 50,20, 10, and 1 percent dilutions in physiological saline solution were tested.
cpH of media after adding the contraceptive at different concentrations.
dResults from duplicate plates.
SOURCE: Singh, Cutler, and Utidjian (145).

analyzed according to the length of time required to kill
the VD organisms and the minimum concentration that was
effective against them.

In 1-,5-, and 1O-minute time exposure tests three contra
ceptives-Cooper Creme, Ortho Creme, and Preceptin Gel
at a 1 percent dilution inhibited the growth of N. gonor
rhoeae bacteria. Eight of the contraceptives were effective
at 10 percent concentration. In a plate-dilution test, Ortho
Creme and Preceptin Gel were effective at a 1 percent
concentration, and eleven others, at a 10 percent concen
tration (see Table 9) (145).

In tests of the effectiveness of various vaginal contracep
tive products against syphilis, an Emko concentrate and
Ortho Creme at a 1 percent concentration immobilized T.
pallidum, the spirochete responsible for syphilis, within 1
to 1.5 minutes; 12 preparations were effective at a 10 per
cent concentration, three at 20 percent, and two at 50 per
cent (see Table 10) (145).

Preliminary results of these tests have been encouraging
and further in vitro and in vivo tests are planned. Progress
in this area is especially important for several reasons:
public health measures have had limited success in con
trolling the spread of venereal disease (147,175); gonor
rhea is becoming more resistant to penicillin therapy
(101,147,153,154); syphilis, although not resistant to
penicillin, is infecting more and more people, an in
creasing proportion of whom react advetsely to the drug.

A vaginal preparation which offers both contraception
and VD prophylaxis might be a major step in preventing
the spread of VD. Such an agent would be the first female
contraceptive method to offer the kind of dual protection,
even to a limited degree, against both venereal disease
and pregnancy which has long been provided by the
condom (35).

Table 10-Dilutions of Contraceptives Required
to Immobilize T. Pallidum Suspension
within 1 to 1.5 Minutes

Name of Contraceptive

Concentration
Number of
Ipercent)
Contraceptives
1

2

Certane Vaginal Jelly, Contra
Foam, Cooper Creme,
Delfen Cream, Delfen
Foam, Emko Concen
trate, Emko Concentrate
+A, Finesse, Immolin
Vaginal Cream-Jel,
Lorophyn Suppositories,
Orthogynol Jelly,
Preceptin Gel

10

12

Contra Creme, Lanesta Gel,
Ramses Vaginal Jelly

20

3

Koromex A Vaginal Jelly,
Milex, Crescent Jelly

50

2

Emko Concentrate +8,
Ortho Cream

SOURCE: Singh, Cutler, and Utidjian 1145).
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